Development and pilot-testing of a cognitive behavioral coping skills group intervention for patients with chronic hepatitis C

Development and pilot-testing of a cognitive behavioral coping skills group intervention for patients with chronic hepatitis C

Psychosocial interventions for patients with chronic hepatitis C viral (HCV) infection are needed to attenuate the impact of extrahepatic symptoms, comorbid conditions, and treatment side effects on HCV health outcomes. We adapted empirically-supported interventions for similar patient populations t...

Full description

Bibliographic Details
Main Authors:	Donna M. Evon, Ph.D., Carol E. Golin, Rachel Ruffin, Michael W. Fried
Format:	Article
Language:	English
Published:	Elsevier 2017-06-01
Series:	Contemporary Clinical Trials Communications
Subjects:	Liver Psychosocial Lifestyle Stress Treatment Direct acting antiviral (DAA) Psychological
Online Access:	http://www.sciencedirect.com/science/article/pii/S2451865416301077

Similar Items

Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C
by: Donna M. Evon, et al.
Published: (2018-06-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents
by: Elnaz Agi, et al.
Published: (2020-01-01)

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort
by: Bernuth S, et al.
Published: (2017-07-01)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
by: Elfi Egmond, et al.

Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go
by: Juan-Carlos Saiz
Published: (2019-08-01)

Homelessness and Hepatitis C: risk factors and treatment
by: Goicoechea, Steven C.
Published: (2018)

Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
by: Elton Dajti, et al.
Published: (2021-06-01)

Rapid Virological Response (RVR) of Daclatasvir and Sofosbuvir Plus Ribavirin in Non-Cirrhotic, Treatment-Naive Patients of Hepatitis C Virus Genotype 3
by: Muhammad Sarfraz, et al.
Published: (2018-12-01)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
by: Leonardo Frazzoni, et al.
Published: (2021-04-01)

Efficacy and safety of direct-acting antiviral agent regimens in a real-world cohort of adult Chinese patients with chronic hepatitis C virus infection
by: Jinyuan Wei, et al.
Published: (2020-06-01)

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China
by: Huan Xia, et al.
Published: (2020-05-01)

Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma
by: Catia Giovannini, et al.
Published: (2020-09-01)

Evaluation of direct-acting antivirals and antiretroviral therapy for HIV-HCV coinfected patients in the United States
by: Rivera, Josef Kyle Concepcion
Published: (2021)

On the cusp of change: New therapeutic modalities for HCV
by: Maribel Rodríguez-Torres
Published: (2010-01-01)

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs
by: Stefania Paolucci, et al.
Published: (2020-02-01)

Genotypic resistance testing of HCV – is there a clinical need?
by: Walker, Andreas, et al.
Published: (2016-08-01)

Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
by: Chih-Chin Kao, et al.
Published: (2018-09-01)

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
by: Bashar Aqel, et al.
Published: (2018-09-01)

Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01)

Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1b
by: Mircea Manuc, et al.
Published: (2021-03-01)

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
by: Giuseppe Bruno, et al.
Published: (2017-09-01)

Response to Interferon-Free Direct Antivirals (DAAS) Treatment in HCV-Related Subcutaneous Lipoma-Like Marginal Zone B-Cell Lymphoma
by: Maria Lucia De Luca, et al.
Published: (2019-08-01)

ERADICATION OF HCV INFECTION IN PATIENTS WITH LIVER CIRRHOSIS: FACTOR OF CANCER PREVENTION OR CARCINOGENESIS?
by: N. A. Malinina, et al.
Published: (2019-06-01)

New era for management of chronic hepatitis C virus using direct antiviral agents: A review
by: Tamer Elbaz, et al.
Published: (2015-05-01)

Outcomes of liver transplantation in the era of modern antiviral therapy for hepatitis C
by: K. Yu. Kokina, et al.
Published: (2021-04-01)

Modelling How Refractoriness to Interferon Compromises Interferon-Free Treatment of Hepatitis C Virus Infection
by: Venugopal, Vishnu
Published: (2018)

Decreased expression of interferon‐stimulated genes in B cells of patients with chronic hepatitis C during interferon‐free therapy potentially suggests the eradication of hepatitis C virus in the B cells: A cohort study
by: Jun Arai, et al.
Published: (2020-09-01)

Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis
by: Tom Domovitz, et al.
Published: (2021-02-01)

Treatment of chronic viral hepatitis C with direct acting antiviral agent: review
by: V A Malov, et al.
Published: (2019-11-01)

Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic
by: Miguel Malespin, et al.
Published: (2019-03-01)

Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
by: Nathalie Alazard-Dany, et al.
Published: (2019-01-01)

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3
by: Muhammad Sarfraz, et al.
Published: (2020-03-01)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
by: Sachiko Omotani, et al.
Published: (2020-04-01)

Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment
by: Amer F, et al.
Published: (2019-09-01)

TREATMENTS OF HEPATITIS C VIRUS LIVER CIRRHOSIS WITH PEGYLAT INTERFERON-RIBAVIRIN AND INTERFERON FREE – COMPARATIVE STUDY
by: S.A. Florescu, et al.
Published: (2016-12-01)

Safety and efficacy of direct-acting antiviral drugs in the treatment of chronic hepatitis C virus infection in patients with thalassemia: a prospective study
by: Elsayed Ghoneem, et al.
Published: (2021-06-01)

Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China
by: Jian Zhang, et al.
Published: (2019-07-01)

Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control
by: Mohamed Mohei El Badry, et al.
Published: (2020-11-01)

Cannot write session to /tmp/vufind_sessions/sess_iri10o1bttl5t4p0du955fs94p